Heron Therapeutics (HRTX) Competitors $1.69 -0.04 (-2.31%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.83%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. PRAX, MENS, SANA, DYN, AMPH, AVDL, GPCR, PHVS, RCUS, and ARDXShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Praxis Precision Medicines (PRAX), Jyong Biotech (MENS), Sana Biotechnology (SANA), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), Avadel Pharmaceuticals (AVDL), Structure Therapeutics (GPCR), Pharvaris (PHVS), Arcus Biosciences (RCUS), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors Praxis Precision Medicines Jyong Biotech Sana Biotechnology Dyne Therapeutics Amphastar Pharmaceuticals Avadel Pharmaceuticals Structure Therapeutics Pharvaris Arcus Biosciences Ardelyx Praxis Precision Medicines (NASDAQ:PRAX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends. Which has more risk and volatility, PRAX or HRTX? Praxis Precision Medicines has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Which has preferable earnings and valuation, PRAX or HRTX? Heron Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Heron Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.55M128.87-$182.82M-$10.72-5.05Heron Therapeutics$148.52M1.74-$13.58M-$0.06-28.17 Does the media prefer PRAX or HRTX? In the previous week, Praxis Precision Medicines had 3 more articles in the media than Heron Therapeutics. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 3 mentions for Heron Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.67 beat Heron Therapeutics' score of 0.64 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PRAX or HRTX? Praxis Precision Medicines presently has a consensus price target of $94.11, suggesting a potential upside of 73.99%. Heron Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 195.86%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of PRAX or HRTX? 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is PRAX or HRTX more profitable? Heron Therapeutics has a net margin of -5.24% compared to Praxis Precision Medicines' net margin of -2,137.48%. Heron Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines-2,137.48% -50.42% -46.74% Heron Therapeutics -5.24%N/A -3.43% SummaryHeron Therapeutics beats Praxis Precision Medicines on 10 of the 16 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$263.94M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-28.178.9728.7823.81Price / Sales1.74437.65372.2066.04Price / CashN/A157.7635.4557.96Price / Book-7.684.838.275.54Net Income-$13.58M$31.62M$3.25B$259.28M7 Day Performance-11.52%-5.28%-3.70%-4.64%1 Month Performance-21.40%4.38%4.34%4.41%1 Year Performance-37.75%-2.49%25.90%17.95% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics3.7275 of 5 stars$1.69-2.3%$5.00+195.9%-39.9%$263.94M$148.52M-28.17300PRAXPraxis Precision Medicines2.4185 of 5 stars$55.65-6.0%$94.11+69.1%-5.0%$1.13B$8.55M-5.19110Analyst ForecastMENSJyong BiotechN/A$14.48+4.9%N/AN/A$1.10BN/A0.0031Positive NewsQuiet Period ExpirationSANASana Biotechnology3.3036 of 5 stars$4.88-1.4%$9.17+87.8%-27.1%$1.10BN/A-5.55380News CoverageUpcoming EarningsGap DownDYNDyne Therapeutics3.5809 of 5 stars$9.31-6.4%$40.63+336.4%-76.1%$1.06BN/A-2.59100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionAMPHAmphastar Pharmaceuticals4.3707 of 5 stars$22.24-0.6%$32.33+45.4%-50.0%$1.05B$730.66M8.062,028News CoverageUpcoming EarningsAVDLAvadel Pharmaceuticals2.6715 of 5 stars$10.83-1.8%$18.33+69.3%-32.9%$1.05B$169.12M-40.1170News CoverageUpcoming EarningsGPCRStructure Therapeutics2.0602 of 5 stars$18.27+1.8%$76.17+316.9%-51.7%$1.05BN/A-21.00136News CoverageUpcoming EarningsPHVSPharvaris1.7483 of 5 stars$20.00-3.0%$36.20+81.0%+25.5%$1.05BN/A-6.6430RCUSArcus Biosciences2.1528 of 5 stars$9.85-3.7%$21.29+116.1%-41.8%$1.04B$258M-2.35500Upcoming EarningsARDXArdelyx4.0323 of 5 stars$4.28-0.2%$10.89+154.4%-21.3%$1.02B$361.71M-19.4590News CoverageUpcoming Earnings Related Companies and Tools Related Companies Praxis Precision Medicines Competitors Jyong Biotech Competitors Sana Biotechnology Competitors Dyne Therapeutics Competitors Amphastar Pharmaceuticals Competitors Avadel Pharmaceuticals Competitors Structure Therapeutics Competitors Pharvaris Competitors Arcus Biosciences Competitors Ardelyx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
